National Engineering Research Center of Cell Products, AmCellGene Engineering Co., Ltd., Tianjin, 300457, China | Tianjin Key Laboratory of Engineering Technologies for Cell Pharmaceutical, Tianjin, 300457, China.
The Postdoctoral Research Station, School of Medicine, Nankai University, Tianjin, 300071, China | Shandong Provincial Key Laboratory of Translational Medicine for Rheumatic and Immune Diseases, Qianfoshan Hospital & The First Affiliated Hospital of Shandong First Medical University, Ji-nan, 250014, China | Institute of Stem Cells, Health-Biotech (Tianjin) Stem Cell Research Institute Co., Ltd., Tianjin, 301700, China.
Curr Stem Cell Res Ther. 2022;17(1):2-12. doi: 10.2174/1574888X16666210712212421.
The outbreak of coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a widespread pandemic globally and seriously threatened public health. Patients with COVID-19 infection, and in particular, those with severe pneumonia-associated acute respiratory distress syndrome (ARDS) manifested rapid disease progression and the resultant high mortality and morbidity. Advances in fundamental and clinical studies have suggested the feasibility of mesenchymal stem/stromal cell (MSC)-based therapy as an inspiring alternative for ARDS administration. However, the systematic characteristics of the MSC-based cytotherapy and underlying mechanism for COVID-19 associated ARDS by bibliometric analyses are still unknowable. Herein, we took advantage of visual analyses to reveal the overview of ARDS-associated updates, core authors and focused issues, as well as to summarize the comprehensive knowledge of the keywords, authors, institutions with the aid of indicated software. Meanwhile, we have provided a brief overview on the molecular mechanisms and discussed the safety and efficacy of MSC-based therapy for ARDS on the basis of clinical trials.
由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引发的 2019 年冠状病毒病(COVID-19)爆发已在全球范围内广泛流行,并严重威胁公众健康。COVID-19 感染患者,特别是伴有严重肺炎相关急性呼吸窘迫综合征(ARDS)的患者,表现出疾病快速进展,导致高死亡率和高发病率。基础和临床研究的进展表明,间充质干细胞/基质细胞(MSC)为基础的治疗作为 ARDS 治疗的一种有希望的替代方法具有可行性。然而,通过文献计量学分析,基于 MSC 的细胞治疗的系统特征和 COVID-19 相关 ARDS 的潜在机制仍不清楚。在此,我们利用可视化分析来揭示 ARDS 相关研究的概述、核心作者和重点问题,并借助相关软件总结关键词、作者、机构的综合知识。同时,我们基于临床试验,对基于 MSC 的治疗 ARDS 的分子机制和安全性及有效性进行了简要概述。